<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110499</url>
  </required_header>
  <id_info>
    <org_study_id>210961-002</org_study_id>
    <nct_id>NCT01110499</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of
      AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in
      the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a
      formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost
      ophthalmic solution 0.03% for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Change From Baseline in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. Data are recorded at Hours 0, 2, 4, 6, 8, and 12. A negative number change from Baseline indicated a reduction in IOP (improvement). Data for bimatoprost-treated eyes are combined across groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Change From Baseline in Average Eye Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Day 29</time_frame>
    <description>IOP is a measurement of the fluid pressure inside the eye. Average IOP is the average of the 2 eyes for each patient at each time point. A negative number change from Baseline indicates a reduction in IOP (improvement). Data are recorded at Hours 0, 2, 4, 6, 8, and 12.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, AGN-210961 Formulation 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, AGN-210961 Formulation 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, bimatoprost ophthalmic solution 0.03%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 1</intervention_name>
    <description>AGN-210961 Formulation 1 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 2</intervention_name>
    <description>AGN-210961 Formulation 2 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 3</intervention_name>
    <description>AGN-210961 Formulation 3 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 4</intervention_name>
    <description>AGN-210961 Formulation 4 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 5</intervention_name>
    <description>AGN-210961 Formulation 5 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 6</intervention_name>
    <description>AGN-210961 Formulation 6 in one eye once daily for 7 days.</description>
    <arm_group_label>Part 1, AGN-210961 Formulation 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-210961 Formulation 7</intervention_name>
    <description>AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.</description>
    <arm_group_label>Part 2, AGN-210961 Formulation 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost ophthalmic solution 0.03%</intervention_name>
    <description>bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.</description>
    <arm_group_label>Part 2, bimatoprost ophthalmic solution 0.03%</arm_group_label>
    <other_name>LUMIGAN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Ocular hypertension or primary open-angle glaucoma in each eye

        Exclusion Criteria:

          -  Any active ocular disease

          -  Anticipated wearing of contact lenses during study

          -  Anticipated use of artificial tears during study

          -  Contraindication to pupil dilatation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2010</study_first_posted>
  <results_first_submitted>May 31, 2013</results_first_submitted>
  <results_first_submitted_qc>July 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2014</results_first_posted>
  <disposition_first_submitted>May 25, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 25, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 1, 2012</disposition_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a 2-part study. Patients were enrolled in and completed Part 1 of the study. Then, based on a review of the data from Part 1, a different formulation was selected for Part 2 (Formulation 7). New patients were then enrolled in Part 2 of the study. No patients from Part 1 were enrolled in Part 2 of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1, AGN-210961 Formulation 1</title>
          <description>AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Part 1, AGN-210961 Formulation 2</title>
          <description>AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Part 1, AGN-210961 Formulation 3</title>
          <description>AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Part 1, AGN-210961 Formulation 4</title>
          <description>AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P5">
          <title>Part 1, AGN-210961 Formulation 5</title>
          <description>AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P6">
          <title>Part 1, AGN-210961 Formulation 6</title>
          <description>AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="P7">
          <title>Part 2, AGN-210961 Formulation 7</title>
          <description>AGN-210961 Formulation 7 (a different formulation from those used in Part 1) in both eyes once daily for 4 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Part 2, Bimatoprost Ophthalmic Solution 0.03%</title>
          <description>bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1, AGN-210961 Formulation 1</title>
          <description>AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Part 1, AGN-210961 Formulation 2</title>
          <description>AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Part 1, AGN-210961 Formulation 3</title>
          <description>AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Part 1, AGN-210961 Formulation 4</title>
          <description>AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Part 1, AGN-210961 Formulation 5</title>
          <description>AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B6">
          <title>Part 1, AGN-210961 Formulation 6</title>
          <description>AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="B7">
          <title>Part 2, AGN-210961 Formulation 7</title>
          <description>AGN-210961 Formulation 7 (a different formulation from those used in Part 1) in both eyes once daily for 4 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Part 2, Bimatoprost Ophthalmic Solution 0.03%</title>
          <description>bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="14"/>
            <count group_id="B7" value="39"/>
            <count group_id="B8" value="40"/>
            <count group_id="B9" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Change From Baseline in Intraocular Pressure (IOP)</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. Data are recorded at Hours 0, 2, 4, 6, 8, and 12. A negative number change from Baseline indicated a reduction in IOP (improvement). Data for bimatoprost-treated eyes are combined across groups.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Safety Population: all treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, AGN-210961 Formulation 1</title>
            <description>AGN-210961 Formulation 1 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Part 1, AGN-210961 Formulation 2</title>
            <description>AGN-210961 Formulation 2 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part 1, AGN-210961 Formulation 3</title>
            <description>AGN-210961 Formulation 3 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Part 1, AGN-210961 Formulation 4</title>
            <description>AGN-210961 Formulation 4 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, AGN-210961 Formulation 5</title>
            <description>AGN-210961 Formulation 5 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O6">
            <title>Part 1, AGN-210961 Formulation 6</title>
            <description>AGN-210961 Formulation 6 in one eye once daily for 7 days.</description>
          </group>
          <group group_id="O7">
            <title>Part 1, Bimatoprost Ophthalmic Solution 0.03%</title>
            <description>bimatoprost ophthalmic solution 0.03% in the other eye in all Part 1 treatment groups once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Intraocular Pressure (IOP)</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. Data are recorded at Hours 0, 2, 4, 6, 8, and 12. A negative number change from Baseline indicated a reduction in IOP (improvement). Data for bimatoprost-treated eyes are combined across groups.</description>
          <population>Safety Population: all treated patients</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4" spread="2.5"/>
                    <measurement group_id="O2" value="25.6" spread="2.71"/>
                    <measurement group_id="O3" value="24.3" spread="1.94"/>
                    <measurement group_id="O4" value="26.7" spread="3.60"/>
                    <measurement group_id="O5" value="24.4" spread="1.54"/>
                    <measurement group_id="O6" value="25.3" spread="2.23"/>
                    <measurement group_id="O7" value="25.3" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="2.18"/>
                    <measurement group_id="O2" value="23.5" spread="2.53"/>
                    <measurement group_id="O3" value="23.6" spread="2.64"/>
                    <measurement group_id="O4" value="23.6" spread="3.27"/>
                    <measurement group_id="O5" value="23.1" spread="3.49"/>
                    <measurement group_id="O6" value="24.1" spread="3.25"/>
                    <measurement group_id="O7" value="23.4" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="2.53"/>
                    <measurement group_id="O2" value="23.1" spread="2.55"/>
                    <measurement group_id="O3" value="23.6" spread="3.64"/>
                    <measurement group_id="O4" value="23.0" spread="3.72"/>
                    <measurement group_id="O5" value="23.1" spread="2.46"/>
                    <measurement group_id="O6" value="23.7" spread="2.49"/>
                    <measurement group_id="O7" value="23.2" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="2.53"/>
                    <measurement group_id="O2" value="22.0" spread="2.46"/>
                    <measurement group_id="O3" value="24.4" spread="4.43"/>
                    <measurement group_id="O4" value="21.9" spread="3.88"/>
                    <measurement group_id="O5" value="22.1" spread="2.60"/>
                    <measurement group_id="O6" value="22.4" spread="2.72"/>
                    <measurement group_id="O7" value="22.5" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="2.84"/>
                    <measurement group_id="O2" value="21.3" spread="2.58"/>
                    <measurement group_id="O3" value="23.2" spread="3.87"/>
                    <measurement group_id="O4" value="22.1" spread="4.04"/>
                    <measurement group_id="O5" value="22.2" spread="2.83"/>
                    <measurement group_id="O6" value="22.9" spread="2.95"/>
                    <measurement group_id="O7" value="22.3" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="2.98"/>
                    <measurement group_id="O2" value="21.6" spread="3.03"/>
                    <measurement group_id="O3" value="21.8" spread="3.86"/>
                    <measurement group_id="O4" value="21.6" spread="4.24"/>
                    <measurement group_id="O5" value="21.3" spread="1.98"/>
                    <measurement group_id="O6" value="20.8" spread="2.44"/>
                    <measurement group_id="O7" value="21.5" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7- Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="4.22"/>
                    <measurement group_id="O2" value="-6.3" spread="4.24"/>
                    <measurement group_id="O3" value="-5.9" spread="4.36"/>
                    <measurement group_id="O4" value="-6.0" spread="3.87"/>
                    <measurement group_id="O5" value="-5.2" spread="3.79"/>
                    <measurement group_id="O6" value="-5.6" spread="3.16"/>
                    <measurement group_id="O7" value="-6.3" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7- Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="3.00"/>
                    <measurement group_id="O2" value="-6.6" spread="2.88"/>
                    <measurement group_id="O3" value="-6.0" spread="2.72"/>
                    <measurement group_id="O4" value="-5.6" spread="2.80"/>
                    <measurement group_id="O5" value="-5.3" spread="3.97"/>
                    <measurement group_id="O6" value="-5.2" spread="3.71"/>
                    <measurement group_id="O7" value="-5.0" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7- Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="4.27"/>
                    <measurement group_id="O2" value="-4.5" spread="2.45"/>
                    <measurement group_id="O3" value="-6.3" spread="4.35"/>
                    <measurement group_id="O4" value="-4.0" spread="2.48"/>
                    <measurement group_id="O5" value="-5.2" spread="3.60"/>
                    <measurement group_id="O6" value="-5.2" spread="3.68"/>
                    <measurement group_id="O7" value="-5.1" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7 - Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="2.23"/>
                    <measurement group_id="O2" value="-4.5" spread="3.03"/>
                    <measurement group_id="O3" value="-6.7" spread="4.05"/>
                    <measurement group_id="O4" value="-3.2" spread="3.49"/>
                    <measurement group_id="O5" value="-5.1" spread="2.23"/>
                    <measurement group_id="O6" value="-4.7" spread="2.63"/>
                    <measurement group_id="O7" value="-5.5" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7- Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="2.91"/>
                    <measurement group_id="O2" value="-4.8" spread="2.45"/>
                    <measurement group_id="O3" value="-5.8" spread="3.31"/>
                    <measurement group_id="O4" value="-4.4" spread="2.49"/>
                    <measurement group_id="O5" value="-5.5" spread="3.28"/>
                    <measurement group_id="O6" value="-4.9" spread="3.94"/>
                    <measurement group_id="O7" value="-6.2" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 7- Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="3.77"/>
                    <measurement group_id="O2" value="-4.9" spread="3.39"/>
                    <measurement group_id="O3" value="-4.8" spread="3.69"/>
                    <measurement group_id="O4" value="-4.8" spread="3.41"/>
                    <measurement group_id="O5" value="-3.7" spread="3.88"/>
                    <measurement group_id="O6" value="-3.7" spread="3.21"/>
                    <measurement group_id="O7" value="-5.6" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Change From Baseline in Average Eye Intraocular Pressure (IOP)</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. Average IOP is the average of the 2 eyes for each patient at each time point. A negative number change from Baseline indicates a reduction in IOP (improvement). Data are recorded at Hours 0, 2, 4, 6, 8, and 12.</description>
        <time_frame>Baseline, Day 29</time_frame>
        <population>Modified Intent to Treat: all randomized and treated patients who provided IOP data for baseline and at least one postbaseline hour 0 assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, AGN-210961 Formulation 7</title>
            <description>AGN-210961 Formulation 7 (a different formulation from those used in Part 1) in both eyes once daily for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Bimatoprost Ophthalmic Solution 0.03%</title>
            <description>bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Change From Baseline in Average Eye Intraocular Pressure (IOP)</title>
          <description>IOP is a measurement of the fluid pressure inside the eye. Average IOP is the average of the 2 eyes for each patient at each time point. A negative number change from Baseline indicates a reduction in IOP (improvement). Data are recorded at Hours 0, 2, 4, 6, 8, and 12.</description>
          <population>Modified Intent to Treat: all randomized and treated patients who provided IOP data for baseline and at least one postbaseline hour 0 assessment</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.63" spread="2.526"/>
                    <measurement group_id="O2" value="24.62" spread="2.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.40" spread="2.072"/>
                    <measurement group_id="O2" value="23.70" spread="3.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.25" spread="2.449"/>
                    <measurement group_id="O2" value="22.51" spread="3.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.97" spread="2.264"/>
                    <measurement group_id="O2" value="22.38" spread="3.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.28" spread="2.896"/>
                    <measurement group_id="O2" value="21.48" spread="3.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.72" spread="3.162"/>
                    <measurement group_id="O2" value="20.94" spread="3.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.44" spread="3.173"/>
                    <measurement group_id="O2" value="-8.63" spread="3.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.40" spread="3.269"/>
                    <measurement group_id="O2" value="-8.51" spread="3.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="3.521"/>
                    <measurement group_id="O2" value="-7.39" spread="3.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.31" spread="3.625"/>
                    <measurement group_id="O2" value="-6.92" spread="3.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.15" spread="3.856"/>
                    <measurement group_id="O2" value="-6.31" spread="4.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 29 - Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="4.086"/>
                    <measurement group_id="O2" value="-5.10" spread="4.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>AEs and SAEs are reported for all treated patients. In Part 1, ocular AEs for bimatoprost treated eye are noted in “Part 1, bimatoprost 0.03% treated eye” only and those for AGN-210961 Formulations 1-6 eyes are noted in “Part 1, AGN-210961 Formulations 1-6”. In Part 1, non-ocular AEs are reported only in “Part 1, AGN-210961 Formulations 1-6” arms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1, AGN-210961 Formulation 1</title>
          <description>AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Part 1, AGN-210961 Formulation 2</title>
          <description>AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Part 1, AGN-210961 Formulation 3</title>
          <description>AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Part 1, AGN-210961 Formulation 4</title>
          <description>AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E5">
          <title>Part 1, AGN-210961 Formulation 5</title>
          <description>AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E6">
          <title>Part 1, AGN-210961 Formulation 6</title>
          <description>AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.</description>
        </group>
        <group group_id="E7">
          <title>Part 1, Bimatoprost Ophthalmic Solution 0.03% Treated Eye</title>
          <description>bimatoprost ophthalmic solution 0.03% in the non-study eye once daily for 7 days (all bimatoprost ophthalmic solution 0.03% treated eyes in Part 1 combined).</description>
        </group>
        <group group_id="E8">
          <title>Part 2, AGN-210961 Formulation 7</title>
          <description>AGN-210961 Formulation 7 (a different formulation from those used in Part 1) in both eyes once daily for 4 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Part 2, Bimatoprost Ophthalmic Solution 0.03%</title>
          <description>bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lip and/or Oral Cavity Cancer</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="19" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Corneal thickening</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Foreign Body Sensation in Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Eye Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

